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Aim Preclinical work indicates that low-density lipoprotein cholesterol (LDL-C) not only drives atherosclerosis by
directing the innate immune response at plaque level but also augments proinflammatory monocyte production in
the bone marrow (BM) compartment. In this study, we aim to unravel the impact of LDL-C on monocyte produc-




A multivariable linear regression analysis in 12 304 individuals of the EPIC-Norfolk prospective population study
showed that LDL-C is associated with monocyte percentage (b = 0.131 [95% CI: 0.036–0.225]; P = 0.007), at the
expense of granulocytes (b = -0.876 [95% CI: -1.046 to -0.705]; P < 0.001). Next, we investigated whether altered
haematopoiesis could explain this monocytic skewing by characterizing CD34þ BM haematopoietic stem and pro-
genitor cells (HSPCs) of patients with familial hypercholesterolaemia (FH) and healthy normocholesterolaemic con-
trols. The HSPC transcriptomic profile of untreated FH patients showed increased gene expression in pathways
involved in HSPC migration and, in agreement with our epidemiological findings, myelomonocytic skewing. Twelve
weeks of cholesterol-lowering treatment reverted the myelomonocytic skewing, but transcriptomic enrichment of
monocyte-associated inflammatory and migratory pathways persisted in HSPCs post-treatment. Lastly, we link
hypercholesterolaemia to perturbed lipid homeostasis in HSPCs, characterized by lipid droplet formation and tran-
scriptomic changes compatible with increased intracellular cholesterol availability.
...................................................................................................................................................................................................
Conclusions Collectively, these data highlight that LDL-C impacts haematopoiesis, promoting both the number and the proin-
flammatory activation of circulating monocytes. Furthermore, this study reveals a potential contributory role of
HSPC transcriptomic reprogramming to residual inflammatory risk in FH patients despite cholesterol-lowering
therapy.
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Introduction
Atherosclerotic cardiovascular disease (CVD) is the leading cause of
death worldwide, despite improved preventive strategies and sur-
vival.1 Low-density lipoprotein cholesterol (LDL-C) is the key driver
of atherosclerotic CVD, making cholesterol-lowering treatment the
cornerstone of CVD prevention.2,3 Although a substantial propor-
tion of cardiovascular (CV) events is prevented by cholesterol-
lowering treatment, residual CV risk is considerable, even in patients
who reach very low plasma LDL-C levels.4 One of the contributors
to residual CV risk is inflammation, which is suggested to be partly
driven by enhanced monocyte activation.5 Targeting the proinflam-
matory monocyte response is therefore considered a potential strat-
egy to reduce inflammatory risk with minimal systemic
immunosuppression.6–8
Mechanistically, atherosclerosis is the result of an unresolved in-
flammatory response of monocytes and monocyte-derived macro-
phages to cholesterol retention in the arterial wall.9 Over the last
decade, it has become increasingly clear that hypercholesterolaemia
aggravates this inflammatory process by enhancing the production
of proinflammatory monocytes in the bone marrow (BM)
compartment.10,11 This is of clinical interest since epidemiological
studies have identified monocyte count as an important CV risk fac-
tor,12,13 whereas translational research has confirmed the association
of a proinflammatory monocyte phenotype with increased inflamma-
tory activity in the arterial wall.14
In steady state, all types of mature blood cells—including
monocytes—are produced in the BM compartment via a process
called haematopoiesis. Following specific stimuli, multipotent
haematopoietic stem and progenitor cells (HSPCs) undergo lin-
eage commitment steps while proliferating and differentiating into
leukocytes, erythrocytes or thrombocytes.15 Animal studies have
shown that hypercholesterolaemia influences this process by pro-
moting HSPC proliferation and myeloid commitment, ultimately
leading to monocytosis and accelerated atherosclerosis.16–18 Also,
alterations in lipid metabolism in HSPCs themselves following, for
example, activation of cholesterol synthesis19 or blocking of chol-
esterol efflux,20–22 enhances HSPC expansion and myeloid
skewing. Together, these studies substantiate that plasma choles-
terol levels and intracellular cholesterol homeostasis have impact
on HSPC proliferation and differentiation.23 We therefore
hypothesized that the enhanced monocyte response in
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LDL-C impacts hematopoiesis, promoting both the number and the proinflammatory activation of circulating monocytes.
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hypercholesterolemic patients5 could be traced back to LDL-C-
mediated disruption of cholesterol homeostasis in HSPCs and
subsequent altered haematopoiesis.
To examine our hypothesis, we performed two human stud-
ies. First, we conducted a mechanistic study in which we per-
formed ex vivo unbiased RNA sequencing (RNAseq) and
functional analyses of CD34þ BM HSPCs (hereafter HSPCs) of
patients with untreated familial hypercholesterolaemia (FH) be-
fore and after cholesterol-lowering treatment, and compared
these results to normocholesterolemic healthy control subjects.
Next, we used epidemiological data to determine the relation-
ship between LDL-C and leucocyte count and differential in the
EPIC-Norfolk study.
Methods
Study population and design
Study population and design for mechanistic analyses in
hypercholesterolemic patients
For mechanistic validation, we conducted a single-centre observational
study between July 2017 and May 2019 at the Amsterdam UMC (location
AMC), The Netherlands. We included untreated FH patients who had an
indication to start lipid-lowering therapy [statin, proprotein convertase
subtilisin/kexin type 9 (PCSK9), and/or ezetimibe] according to their
treating physician. FH was defined as having a mutation in one of the
known FH-causing genes (LDLR, PCSK9, APOB) or, in the absence of such
mutation after genetic testing, having a Dutch Lipid Clinic Network score
>_ 6 (=probable or definite FH).24 Exclusion criteria included active smok-
ing, established CVD and recent use (<3 months) of cholesterol-lowering
drugs. The healthy controls were age, sex, and body mass index (BMI)
matched with the FH patients. After inclusion, FH patients underwent
blood withdrawal and a sternal bone marrow aspiration at baseline and
after 12 weeks of lipid-lowering therapy. The healthy controls underwent
these procedures once. All participants provided written informed con-
sent. The study protocol was approved by the ethics committee of the
Amsterdam UMC and was conducted according to the principles of the
Declaration of Helsinki.
Study population and design for epidemiological analysis
in the EPIC-Norfolk cohort
For the assessment of the correlation between LDL-C, apolipoprotein B
(ApoB) and leucocyte count and differential, we used data from the
European Prospective Investigation into Cancer in Norfolk (EPIC-
Norfolk) study.25 Between 1993 and 1997, 25 639 subjects were
recruited from general practices and included in this study. The study
protocol was approved by the ethics committee of the Norwich District
Health Authority and all study participants gave written informed consent
prior to enrolment.
Bone marrow experiments
All the laboratory experiments and bioinformatics analyses regarding
HSPC characterization are available in detail in the Supplementary mater-
ial online.
Statistical approach
Statistical analysis of the EPIC-Norfolk data
After excluding subjects with C-reactive protein (CRP) >_10 g/L [to min-
imize bias caused by (acute) infections] and missing leucocyte count and
differential values, we performed a univariate regression analysis for LDL-
C on leucocyte count, and monocyte, lymphocyte and granulocyte per-
centage in 12 304 individuals. In addition, we performed multivariable
analyses to adjust for age, sex, BMI, smoking, and CRP.
Quantification and statistical analyses FH study
All data were analysed using R version 3.6.3 (R Core Team, Vienna,
Austria), SPSS version 25 (SPSS Inc., Chicago, IL, USA), and Graphpad
Prism 8 (La Jolla, CA, USA). Data are presented as mean ± standard devi-
ation for normally distributed data, median (interquartile range) for non-
normally distributed data, or as a number with percentage from total (%)
for categorical variables. Changes in biochemical measurements after
cholesterol-lowering treatment were assessed using a paired Students t-
test or Wilcoxon signed-rank test for normally and non-normally distrib-
uted data, respectively. Unpaired analyses to compare patients with the
healthy control group were performed using an unpaired Student’s t-test




patients exhibit myelomonocytic skewing
and a promigratory profile
In an ex vivo study, we evaluated the impact of hypercholesterol-
aemia on HSPCs in the BM compartment at a cellular level. We
included 10 untreated FH patients (mean baseline LDL-C
6.0± 2.5 mmol/L; corresponding with Dutch reference LDL-
C > 99th percentile26) and 9 age, sex and BMI matched normo-
cholesterolemic healthy controls (mean LDL-C 3.3± 0.6 mmol/L;
corresponding with Dutch reference LDL-C < 50th percentile26).
Leukocyte (differential) count did not significantly differ between
the two groups (additional baseline characteristics are shown in
Supplementary material online, Table S1). In all study participants,
a sternal BM aspirate was obtained, from which we isolated and
purified CD34þ HSPCs.
First, principle component analysis of the HSPC RNAseq data
showed a separation of the untreated FH patients and healthy con-
trols (Figure 1A). Differential gene expression analysis revealed 1892
differentially expressed genes (DEGs) with a false discovery rate
(FDR) of <0.05 (Figure 1B), of which 1642 genes were up- and 250
genes were downregulated in the untreated FH patients vs. healthy
controls. Gene ontology (GO) term analysis of the significantly upre-
gulated genes showed predominantly enrichment in pathways related
to cell migration (Figure 1C). Most genes in these upregulated path-
ways, including FLT1, NRP1, CCL2, and CXCL12 (Figure 1B), are mem-
bers of the vascular endothelial growth factor (VEGF) and
chemokine family, respectively. Interestingly, these migratory associ-
ated genes promote myeloid progenitor and monocyte mobilization
from the BM compartment and increase macrophage and foam cell
content in atherosclerotic lesions.27–29 Gene set enrichment analysis
(GSEA) underlined this finding, showing enrichment of the gene set
‘monocyte chemotaxis’ (FDR = 0.007) in untreated FH patients
(Figure 1D). Of note, VEGF receptors (VEGFRs) belong to the large
superfamily of receptor tyrosine kinases (RTKs) that play a central
role in fundamental cellular functions including proliferation, differen-
tiation, metabolism and migration.30 In line, pathway analysis showed















.enrichment in the RTK signalling pathway (Figure 1C) and the small
GTPase mediated signalling pathway (Figure 1C), of which the latter
are important downstream effectors for many cell surface receptors
including RTKs.31 The top significantly upregulated genes in these
two pathways included KDR, a gene encoding VEGFR 2, but also the
non-VEGFR RTKs ALK, AXL, and EGFR (Figure 1E). Interestingly, up-
regulation of PDK4, a gene encoding a key metabolic mitochondrial
protein promoting the switch from glucose to fatty acid oxidation,
Figure 1 HSPCs of hypercholesterolemic patients exhibit myelomonocytic skewing and a promigratory profile. (A) Principle component analysis
plot of RNAseq data of isolated CD34þ HSPCs. (B) Volcano plot showing differentially expressed genes. (C) Top 10 most significant enriched path-
ways using gene ontology (GO) term analysis of significantly upregulated genes in untreated FH patients vs. healthy controls. (D) Enrichment of gene
set ‘GO monocyte chemotaxis’. (E) Heatmap of most significant upregulated genes in GO RTK signalling and small GTP-ase mediated signalling in un-
treated FH patients; black dot indicates mutation proven FH. (F) Top 10 most significant enriched pathways using GO term analysis of significantly
downregulated genes in untreated FH patients vs. healthy controls. (G) Enrichment of gene set ‘REACTOME transcriptional regulation of granulopoi-
esis’. (H) Normalized gene counts for KITLG and IL7. P-values are adjusted for multiple testing using Bonferroni–Hochberg correction. Triangle sym-
bol indicates proven LDLR mutation, a square indicates proven APOB mutation, a dot indicates no FH mutation. (I–K) Enrichment of gene sets
‘REACTOME cell cycle checkpoints’, ‘REACTOME RUNX1 regulates transcription of genes involved in differentiation of HSCs’, and ‘REACTOME
TCA cycle and respiratory electron transport’. (L) Percentage CD34þ HSPC in bone marrow compartment measured by flow cytometry. Data are
mean ± SD. Triangle symbol indicates proven LDLR mutation, a square indicates proven APOB mutation, and a dot indicates no FH mutation.
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Figure 2 Cholesterol-lowering treatment mitigates decreased HSPC differentiation and myelomonocytic skewing. (A) Principle component ana-
lysis plot of RNAseq data of isolated CD34þ HSPCs. (B) Volcano plot showing differentially expressed genes before vs. after cholesterol-lowering
treatment in FH patients. (C) Top 10 most significant enriched pathways using gene ontology (GO) term analysis of significantly downregulated genes
in treated FH patients vs. untreated FH patients. (D) Top 10 most significant enriched pathways using GO term analysis of significantly upregulated
genes in treated FH patients vs. untreated FH patients. (E) Enrichment of gene set ‘KEGG oxidative phosphorylation’. (F) Heatmap of most significant-
ly differentially expressed gene in KEGG pathway OXPHOS in treated FH patients, black dot indicates mutation proven FH. (G) Seahorse extracellu-
lar flux analysis of Oxygen Consumption Rate (OCR) in CD34þ HSPCs. (H–J) Enrichment of gene sets relating to HSPC proliferation and
differentiation. (K) Normalized read counts for several genes encoding regulators of myeloid HSPC differentiation. P-values are adjusted for multiple
testing using Bonferroni–Hochberg correction. Triangle symbol indicates proven LDLR mutation, a square indicates proven APOB mutation, and a dot
indicates no FH mutation. (L) Granulocyte monocyte colony forming unit (CFU-GM) and burst-forming unit-erythroid (BFU-e) assay. Data are mean
± SD. Triangle symbol indicates proven LDLR mutation, a square indicates proven APOB mutation, and a dot indicates no FH mutation.

































































































suggests that fatty acids are the preferred substrates for oxidation in
HSPCs of untreated FH patients32 (Figure 1E).
GO term analysis of the significantly downregulated genes in un-
treated FH patients demonstrated enrichment of the pathways ‘mye-
loid leucocyte activation’ and ‘antibacterial humoral response’ (Figure
1F). In accordance with our epidemiological data showing a negative
association of LDL-C with granulocyte percentage, these two path-
ways predominantly consisted of downregulated granulocytic associ-
ated genes (15 out of 16 genes), which was also reflected by a down-
regulation of the gene set ‘transcriptional regulation of granulopoie-
sis’ in untreated FH patients (FDR = 0.000) (Figure 1G). In addition to
these monocytic-skewed transcriptomic changes in HSPCs of un-
treated FH patients, an up-regulation of KITLG, encoding an important
regulator of stem cell survival and myelopoiesis called stem cell factor
(SCF)33 was observed, in addition to down-regulation of lymphoid-
associated gene IL734 (Figure 1H).
HSPCs give rise to mature blood cells through cell proliferation
and differentiation.35 Interestingly, GSEA showed that gene sets
related to cell cycle and differentiation were negatively enriched in
untreated FH patients (FDR = 0.000 for both) (Figure 1I–J).
Metabolically, this was in line with a concordant negative enrichment
of the oxidized phosphorylation (OXPHOS) gene set (FDR = 0.000)
(Figure 1K), which is a metabolic programme used in more proliferat-
ing and mitochondrial active HSPCs.36,37 The decreased gene
expression associated with HSPC differentiation, in addition to the
up-regulation of stem cell survival regulator KITLG, coincided with a
1.4-fold increase of the percentage CD34þ HSPCs in the BM com-
partment (P = 0.004) (Figure 1L), measured by flow cytometry. Taken
together, the HSPC transcriptome of untreated FH patients differs
from healthy controls, hallmarked by global up-regulation of promi-




skewing in the BM compartment
Following the first BM aspiration, FH patients received maximally tol-
erated cholesterol-lowering treatment by either a statin, a PCSK9
antibody or a combination, with or without ezetimibe (Supplemen-
tary material online, Table S2). After 12 weeks of treatment, a mean
66% reduction in plasma LDL-C levels was achieved (P < 0.001),
resulting in a mean post-treatment plasma LDL-C level of
1.89± 1.16 mmol/L (Supplementary material online, Table S2). No
significant changes in leucocyte (-0.02 [1.25]; P = 0.961) and mono-
cyte count (0.12 [1.48]; P = 0.803) were observed.
After 12 weeks of treatment, HSPC gene expression demon-
strated a trend towards normalization of the transcriptomic profile
(Figure 2A). Pairwise comparison of the transcriptomic profile before
vs. after treatment showed 2462 significantly DEGs, of which 940
genes were upregulated and 1522 genes were downregulated after
treatment (Figure 2B). GO term analysis of the significantly downre-
gulated genes showed predominantly enrichment of pathways
involved in cell motility (Figure 2C). In addition, GO term analysis of
the significantly upregulated genes and GSEA showed predominantly
enrichment of pathways implicated in OXPHOS (Figure 2D–F). To
functionally validate these findings, we measured the oxygen
consumption rate in HSPCs by Seahorse Flux Analysis. As expected
and while not significant, basal respiration was almost 70% lower
(P = 0.067) in untreated FH patients vs. healthy controls, and was sig-
nificantly increased after cholesterol-lowering therapy (P = 0.029)
(Figure 2G), following the OXPHOS gene expression pattern seen in
the RNAseq.
Since OXPHOS fluxes are higher in more proliferative and differ-
entiated HSPCs,36,37 we examined whether gene sets involved in
proliferation and HSPC differentiation were concomitantly increased
after cholesterol-lowering therapy. Indeed, GSEA confirmed enrich-
ment of the cell cycle and RUNX1-mediated differentiation gene sets
in FH patients after treatment (FDR = 0.000 and FDR <0.001, re-
spectively) (Figure 2H and I). Earlier we noted that the attenuation of
genes involved in granulocyte differentiation was most prominent in
untreated FH patients compared to healthy controls. Interestingly,
both GO term analysis and GSEA revealed reversibility of this effect,
showing significantly increased gene expression associated with neu-
trophil activation (Figure 2D) and granulocyte differentiation (Figure
2J), respectively. Alleviation of decreased gene expression in path-
ways involved in HSPC differentiation was further supported by sig-
nificant enrichment of gene sets involved in lymphopoiesis,
erythropoiesis, and megakaryopoiesis, whereas the gene set involved
in monocytopoiesis was unaffected (FDR = 0.994) (Supplementary
material online, Figure S1). More specifically, expression of key tran-
scriptional determinants of myeloid progenitor commitment GATA1
(inducing megakaryo-erythroid commitment), and CEBPA with its tar-
get gene EVI2B (inducing granulocytic over monocytic commitment)
significantly increased after cholesterol-lowering treatment (Figure
2K).35,38,39 These data, including the up-regulation of CEBPA in the
presence of non-significant change in PU.1 expression, indicate
reduced myelomonocytic skewing in HSPCs of treated FH patients
(Figure 2K).39 A significant decrease in functional ex vivo progenitor
capacity of the colony-forming unit of granulocytes and monocytes
(CFU-GM) (-26.2%; P = 0.028) in the presence of a significant in-
crease of CEPBA, and no effect on progenitor capacity of the burst-
forming unit of erythrocytes (BFU-e) (-5.3%, P = 0.751; Figure 2L), fur-
ther supports reduced myelomonocytic skewing after cholesterol-
lowering treatment, as observed in the gene expression data.
Persistent proinflammatory and
promigratory gene expression in HSPCs
after cholesterol-lowering treatment
We previously described a persistent hyper responsiveness of circu-
lating monocytes in treated FH patients termed ‘trained immunity’.5
Since this immune memory persists beyond the short lifespan (hours
to days) of circulating monocytes, it has been hypothesized that
cholesterol-induced reprogramming of the long-lived progenitors of
monocytes maintain this innate immune memory.5,18 To examine this
hypothesis, we compared the HSPC transcriptional profile of the FH
patients post-treatment to healthy controls.
Whereas we found 1892 significantly DEGs in untreated FH
patients vs. healthy controls (Figure 1B), only 133 genes were differen-
tially expressed after treatment compared to healthy controls (Figure
3A). Interestingly, 128 out of the 131 upregulated genes were also sig-
nificantly upregulated before treatment (Figure 3B). GO term analysis
of these genes showed enrichment of the ‘chemotaxis’ and ‘acute
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Figure 3 Persistent proinflammatory and promigratory gene expression in HSPCs after cholesterol-lowering treatment. (A) Volcano plot showing
differentially expressed genes in treated FH patients vs. healthy controls. (B) Venn diagram indicating the number of significantly upregulated genes in
untreated FH patients vs. healthy controls, and in treated FH patients vs. healthy controls. (C) Top 10 most significant enriched pathways in treated
FH patients vs. healthy controls. (D) Enrichment of gene set ‘GO regulation of lipopolysaccharide mediated signalling pathway’. (E) Heatmap of most
significant differentially expressed genes in GO chemotaxis and GO acute inflammatory response pathways in treated FH patients; black dot indicates
mutation proven FH. (G) Enrichment of gene set ‘GO monocyte chemotaxis’. (G–J) CXCR4 expression on CD34þ HSPC, CCR2 expression on cir-
culating and bone marrow CD14þ monocytes, and monocyte subsets (CD14, CD16) in BM measured by flow cytometry. Data are mean ± SD.
Triangle symbol indicates proven LDLR mutation, a square indicates proven APOB mutation, and a dot indicates no FH mutation.







































inflammatory response’ pathway and GSEA revealed enrichment of
the gene set ‘regulation of lipopolysaccharide (LPS) mediated signal-
ling pathway’ (FDR = 0.019) (Figure 3C and D). This is in line with our
previous findings showing that the trained immunity phenotype of cir-
culating monocytes of FH patients is hallmarked by persistent
enhanced cytokine production after LPS stimulation ex vivo.5 Among
the most upregulated inflammatory genes were plaque macrophage
marker CD163 (Klco et al., 2011)40 and PLA2G7, which encodes
lipoprotein-associated phospholipase A2 (Lp-PLA2) (Figure 3E). Lp-
PLA2 is an enzyme produced by plaque macrophages, serves as a
marker for vulnerable plaques and is a strong predictor of CVD.41,42
Also, genes involved in chemotaxis were persistently elevated in
HSPCs of treated FH patients, including CCL2, CXCL12, and VCAM1
(Figure 3E), with concomitant enrichment of the gene set ‘monocyte
chemotaxis’ (Figure 3F). This gene expression profile coincided with
persistent decreased cell surface expression of BM homing receptor
CXCR4 on CD34þ HSPCs (Figure 3G and Supplementary material
online, Figure S2), and sustained increased CCR2 cell surface expres-
sion on both BM (Figure 3H and Supplementary material online, Figure
S2) and circulating CD14þ monocytes (Figure 3I) after treatment.
Analysis of the monocyte subset distribution in the BM compartment
did not show any significant differences (Figure 3J). Also, we did not
find significant correlations between CCR2 expression on circulating
monocytes and CCR2 expression on bone marrow monocytes, nor
with CXCR4 expression on CD34þ HSPCs (Supplementary material
online, Figure S3). Altogether, these results indicate that transcrip-
tomic reprogramming of HSPCs could contribute to the trained im-
munity phenotype found in circulating monocytes of FH patients.
Both hypercholesterolaemia and
cholesterol-lowering treatment affect
lipid homeostasis in HSPCs of FH
patients
Disrupted lipid homeostasis in HSPCs has major impact on HSPC
behaviour.10,23 Moreover, preclinical studies have linked altered
lipid metabolism in myeloid progenitors to trained immunity.18,43
Indeed, the top 25 of most significantly overexpressed gene sets in
Figure 4 Both hypercholesterolaemia and cholesterol-lowering treatment affects lipid homeostasis in HSPCs of FH patients. (A–C) Enrichment of
gene sets related to lipid homeostasis. (D) Lipid droplet count in lipid droplet positive CD34þ HSPCs. Data are mean ± SD. (E) Representative
images of CD34þ HSPC stained with Nile red. (F and G) Normalized read counts for genes related to lipid homeostasis. P-values are adjusted for
multiplicity using Bonferroni correction. Triangle symbol indicates proven LDLR mutation, a square indicates proven APOB mutation, and a dot indi-
cates no FH mutation. (H) Enrichment of gene set ‘GO lipoprotein metabolic process’.




























































..untreated FH patients compared to healthy controls included
gene sets ‘cholesterol storage’, ‘lipid metabolism’, and ‘lipid diges-
tion mobilization and transport’ (FDR = 0.007, 0.005, and 0.038,
respectively) (Figure 4A–C). In parallel, staining of intracellular lipid
droplets (LDs) by Nile Red demonstrated an increased number of
LDs in HSPCs of untreated FH patients compared to healthy con-
trols (Figure 4D and E). Cells form LDs in reaction to lipid overload
to prevent lipotoxicity.44 In line with GSEA, also other compensa-
tory pathways to lower intracellular cholesterol content were
observed in HSPCs of untreated FH patients, including significant
up-regulation of cholesterol efflux transporter gene expression of
ABCA1 and ABCG1 (Figure 4F). In turn, cholesterol-lowering treat-
ment led to normalization of intracellular LD number (Figure 4D
and E). This coincided with a significant reduction of ABCA1 and
ABCG1 (Figure 4F). Lastly, PPARD and PPARG, encoding lipid sensors
peroxisome proliferator-activated receptor delta and gamma, re-
spectively, were significantly upregulated before treatment (Figure
4G). After cholesterol-lowering treatment, PPARD expression
decreased, whereas PPARG remained significantly upregulated
(Figure 4G). This persistent up-regulation of PPARG post-treatment
corresponded with enrichment of the gene set ‘lipid metabolism’
in treated FH patient vs. healthy controls (Figure 4H).
LDL-C is positively associated with
monocyte percentage but inversely
associated with granulocyte percentage
To assess the impact of plasma LDL-C level (mmol/L) on leucocyte
count (109/L) and differential (% and count), we performed a linear
regression analysis using data from 12 304 individuals participating in
the EPIC-Norfolk prospective population study (Supplementary ma-
terial online, Table S3). LDL-C was not significantly associated with
leucocyte count (b = -0.017, 95% CI (-0.046 to 0.012); P = 0.251);
whereas we did find a significant positive association between LDL-C
and monocyte percentage, also after adjustment for age, sex, BMI,
smoking, CRP and leucocyte count [b = 0.131, 95% CI (0.036–0.225);
P = 0.007]. Conversely, LDL-C was inversely associated with granulo-
cyte percentage [b = -0.876, 95% CI (-1.046 to -0.705); P < 0.001]
(Table 1). The discrepancy between the positive vs. negative associ-
ation of monocyte and granulocyte percentage with LDL-C respect-
ively suggests that LDL-C skews haematopoiesis favouring monocyte
over granulocyte production, since both immune cells arise from the
same bipotential haematopoietic granulocyte–monocyte progenitor
(GMP).35 We found a similar association pattern between LDL-C and
monocyte and granulocyte count (Supplementary material online,
Tables S4 and S5). Interestingly, ApoB also shows a reciprocal associ-
ation with monocytes and granulocytes, whereas ApoA1 does not
show these associations (Supplementary material online, Table S6).
Discussion
Here, we report epidemiological and mechanistic evidence for a
causal role of LDL-C in driving the production of proinflammatory
monocytes at the BM level in hypercholesterolemic patients.
Multivariable regression analysis of LDL-C to leucocyte differential
count in over 12 000 individuals of the EPIC-Norfolk study showed a
positive association with monocyte percentage, and a negative associ-
ation with granulocyte percentage. Ex vivo BM analyses demonstrated
that HSPCs of untreated FH patients are hallmarked by myelomono-
cytic skewing and a promigratory phenotype, coinciding with per-
turbed intracellular lipid homeostasis. Twelve weeks of cholesterol-
lowering treatment largely reverted these HSPC alterations.
However, despite normalization of plasma LDL-C levels, gene
expression involved in monocyte and macrophage-mediated inflam-
mation and migration remained upregulated in HSPCs of treated FH
patients compared to healthy controls (Graphical abstract) .
.............................................. ............................................ ..............................................
....................................................................................................................................................................................................................
Table 1 Relationship between LDL-C and leucocyte differential count (n 5 12 304 individuals, general population of
the EPIC-Norfolk cohort)
Monocytes (%) Granulocytes (%) Lymphocytes (%)


























Data are standardized coefficient (b) with 95% CI.
Unadjusted model: univariate linear regression analysis of plasma LDL-C level (mmol/L) and leucocyte number (109/L), percentage monocytes, granulocytes, or lymphocytes.
Model 1: adjusted for age and sex. Model 2: adjusted for Model 1, total white blood cell count, body mass index, smoking, and C-reactive protein. Betas are reported for each
standard deviation increase in LDL-C. The variance inflation factors of all predictor variables were <1.3. R2 monocyte percentage Model 2: 0.0225. R2 granulocyte percentage
Model 2: 0.06384.
R2 lymphocyte percentage Model 2: 0.06557.
CI, confidence interval.

































































































LDL-C is epidemiologically and
mechanistically linked to enhanced
monocyte production
Our findings in the EPIC-Norfolk cohort revealed no association of
LDL-C with leucocyte count and opposing associations with monocyte
and granulocyte percentage, independently of CRP levels. These results
suggest that the association of LDL-C with specifically monocyte count
is not merely a reflection of the low-grade inflammatory state hallmark-
ing patients with increased CV risk, but could imply an LDL-C-specific
biological effect on leucocyte subset formation. These findings were vali-
dated mechanistically, where we showed that the HSPC transcriptomic
profile was characterized by myelomonocytic skewing in untreated FH
patients. Notably, we demonstrated that the myelomonocytic skewed
transcriptomic profile largely normalized after cholesterol-lowering
treatment, including up-regulation of master regulator and promotor of
granulopoiesis CEPBA.38 Our results are in line with previous preclinical
findings demonstrating that hypercholesterolaemia-induced myeloid
skewing was in part the result of transcriptional reprogramming of the
bipotential GMPs.18 Combined, our epidemiological and mechanistic
results support that LDL-C promotes monocyte production in the BM
compartment at least in part via modulated GMP fate, thereby impeding
granulocytic differentiation. Of note, in the absence of a lymphoid
skewed transcriptomic pattern in BM HSPCs of untreated FH patients,
the significant positive association between LDL-C and lymphocyte
number in the EPIC-Norfolk study may imply a positive effect of hyper-
cholesterolaemia on extramedullary lymphopoiesis.
LDL-C promotes promigratory phenotype
of monocytes and their progenitors
Besides increased monocyte number, also the promigratory phenotype
of monocytes and their progenitors contribute to accelerated athero-
sclerosis. In this respect, we observed an up-regulation of promigratory
genes in HSPCs of untreated FH patients, including FLT1. This is of inter-
est, since blocking of Flt1 in a hypercholesterolemic mouse model,
abrogated myeloid progenitor egress from the BM compartment into
the circulation, which coincided with decreased macrophage content in
atherosclerotic lesions.27 Furthermore, we observed decreased cell
surface expression of the BM homing receptor CXCR4 on HSPCs of
untreated FH patients of which its down-regulation has been described
to promote HSPC mobilization.45 Indeed, previous human studies have
linked hypercholesterolaemia to HSPC migration, evidenced by an as-
sociation between total cholesterol levels and circulating CD34þ
HSPCs.46,47 In line, we previously showed that circulating monocytes of
FH patients have increased CCR2 cell surface expression,5,48 facilitating
monocyte migration into the atherosclerotic plaque.49 Interestingly, we
here show that CD14þ monocytes in the BM compartment of FH
patients also have persistent increased CCR2 cell surface expression
after cholesterol-lowering treatment. The persistent CCR2 expression
on both BM as circulating monocytes and concomitant persistent
promigratory HSPC transcriptomic profile in treated FH patients
implies hypercholesterolaemia-induced HSPC priming in vivo.
Disrupted lipid homeostasis linked to
altered HSPC behaviour
Preclinical work has established that hypercholesterolaemia directly
impacts HSPCs and their behaviour.10 Here, we observed that
increased plasma LDL-C levels lead to a profound increase in LD
number in HSPCs of untreated FH patients, despite compensatory
up-regulation of cholesterol efflux transporter genes ABCA1 and
ABCG1. Interestingly, in parallel of the increased LD number in
HSPCs, we found at both transcriptional as functional level decreased
mitochondrial OXPHOS in HSPCs of untreated FH patients and
increased PDK4 expression, marking fatty acid oxidation. Inhibition of
OXPHOS has been described in the setting of excess intracellular
lipid accumulation50 and could have driven the observed differenti-
ation impairment of HSPCs in untreated FH patients.51
Corroborating these findings, normalization of plasma LDL-C levels
following cholesterol-lowering treatment coincided with reduced LD
number in HSPCs, in addition to an increase in OXPHOS and allevi-
ation of the reduced differentiation. However, the reduction in
OXPHOS could also be a passive reflection of the observed
increased percentage of upstream HS(P)Cs in untreated FH patients.
Future studies on whether these aforementioned metabolic changes
drive monocytic biased differentiation of HSPCs, and via which mech-
anisms the different cholesterol-lowering treatment modalities im-
pact these changes, are therefore warranted.
Clinical implications
Lessons from the CANTOS trial that targeting inflammation along-
side cholesterol-lowering therapy is able to further reduce CVD
risk,52 has fuelled the search for other anti-inflammatory therapies to
combat (residual) inflammatory CVD risk. Our study suggests that
even after cholesterol-lowering treatment modulated haematopoi-
esis contributes to the pro-atherogenic monocyte response in hyper-
cholesterolemic patients, highlighting that BM HSPCs could serve as a
new therapeutic target. For example, targeting mobilization of mono-
cytes and their precursors has already been suggested to mitigate
accelerated atherosclerosis post-myocardial infarction, whereas our
findings emphasize a potentially beneficial effect in the chronic inflam-
matory setting as well.27,53 However, targeting HSPCs is probably
more complex, since several preclinical studies have established that
the changes in HSPCs contributing to prolonged monocyte activation
are multifaceted, with metabolic, transcriptomic, and epigenetic alter-
ations.18,43,54 Especially in the context of trained immunity, further re-
search in hypercholesterolemic patients is warranted, to further
investigate whether the observed transcriptomic (and metabolic)
HSPC reprogramming is accompanied by epigenetic alterations in
these cells. In addition, other CV risk factors including sleep depriv-
ation, diabetes mellitus, and lack of exercise contribute to proathero-
genic changes in haematopoiesis.55–57 It would be of interest to
further investigate how a combination of these risk factors and the
patient’s genetic background impact haematopoiesis and ultimately
atherogenesis, both in the acute setting of an ischaemic event and in
the setting of chronic inflammation.
Conclusion
In conclusion, this study provides epidemiological and mechanistic
evidence that hypercholesterolaemia modulates HSPC behaviour in
the BM compartment, thereby enhancing proinflammatory monocyte
production in patients. Moreover, persistent promigratory and proin-
flammatory gene expression in HSPCs despite normalization of

































































































plasma LDL-C levels suggests that prolonged monocyte activation
originates in the BM compartment of hypercholesterolemic patients.
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Supplementary material is available at European Heart Journal online.
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